Aptose Biosciences to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
05 Setembro 2017 - 9:30AM
Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage
company developing highly differentiated therapeutics that target
the underlying mechanisms of cancer, today announced that William
G. Rice, Chairman, President and Chief Executive Officer, and
Gregory K. Chow, Senior Vice President and Chief Financial Officer,
will participate at the 19th Annual Rodman & Renshaw Global
Investment Conference, sponsored by H.C. Wainright & Co., LLC.,
on Monday, September 11, 2017 at 9:35 a.m. ET at the Lotte New York
Palace Hotel in New York, NY.
Dr. Rice will provide a corporate overview of
the Company’s recent activities and strategic direction.
Time: |
|
|
|
|
9:35 a.m. ET |
Date: |
|
|
|
|
Monday, September 11,
2017 |
Location: |
|
|
|
|
Lotte New York Palace
Hotel, New York, NY |
|
|
|
|
|
|
A live webcast of the Aptose presentation will be accessible by
visiting:
http://wsw.com/webcast/rrshq27/apto
The webcast will be archived shortly after the
live event and will be available for 90 days through the Aptose
website at www.aptose.com
About Aptose
Aptose Biosciences is a clinical-stage
biotechnology company committed to developing personalized
therapies addressing unmet medical needs in oncology. Aptose is
advancing new therapeutics focused on novel cellular targets on the
leading edge of cancer. The Company's small molecule cancer
therapeutics pipeline includes products designed to provide single
agent efficacy and to enhance the efficacy of other anti-cancer
therapies and regimens without overlapping toxicities. For further
information, please visit www.aptose.com.
For further information, please contact:
Aptose Biosciences
Greg Chow, CFO
647-479-9828
gchow@aptose.com
SMP Communications
Susan Pietropaolo
201-923-2049
susan@smpcommunications.com
Aptose Biosciences (TSX:APS)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Aptose Biosciences (TSX:APS)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024